Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-12 · accession 0001062993-24-003237 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-14 | 2024-02-12 | ENTA | Luu Brendan | Chief Business Off | A - Grant | $0.00 | +3,320 | 40.1K | +9% | $0 | |
| 2024-02-14 | 2024-02-12 | ENTA | Luu Brendan | Chief Business Off | F - Tax | $12.41 | -973 | 39.1K | -2% | -$12.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-12 | A | A | 3,320 | $0.00 | 40,056 | D | — | — | (F1) Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2022-2023 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2024. |
| 2 | Common | Common Stock | 2024-02-12 | F | D | 973 | $12.41 | 39,083 | D | — | — | (F2) Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU awards. |